Erythromycin Cyclocarbonate

Basic Information

View in Editor

CAS Number

55224-05-0

Molecular Formula

C38H65NO14

Molecular Weight

759.93 g/mol

Chemical Classification

Basic Chemical Raw Materials Organic Chemicals Carboxylic Acids

Basic Chemical Raw Materials Organic Chemicals Ketones

Basic Chemical Raw Materials Organic Chemicals Esters

Basic Chemical Raw Materials Organic Chemicals Ethers

Basic Chemical Raw Materials Organic Chemicals Heterocyclic Compounds

Pharmaceutical Chemicals Pharmaceutical Intermediates Heterocyclic Intermediates

Fine Chemicals Surfactants Anionic Surfactants

Polymers and Plastics Thermoplastics Polyolefins

Laboratory Chemicals Research Chemicals Biochemical Reagents

Basic Physical Properties

Boiling Point

859.8°C at 760 mmHg

SMILES

View in Editor

CCC1C2(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC3CC(C(C(O3)C)O)(C)OC)C)OC4C(C(CC(O4)C)N(C)C)O)(C)O)C)C)OC(=O)O2)C

InChI

InChI=1S/C38H65NO14/c1-14-25-38(10)32(52-35(44)53-38)20(4)27(40)18(2)16-36(8,45)31(51-34-28(41)24(39(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-37(9,46-13)30(42)23(7)48-26/h18-26,28-32,34,41-42,45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30+,31-,32-,34+,36-,37-,38-/m1/s1

InChIKey

NKLGIWNNVDPGCA-ZDYKNUMJSA-N

LogP

2.9678000000000058

Topological Polar Surface Area

188.98 Å²

Hydrogen Bond Donor/Acceptor

3 / 15

Complexity

1300

Safety Information

View Safety Information

Hazard Statement

H302 Harmful if swallowed
Acute toxicity, oral

H315 Causes skin irritation
Skin corrosion/irritation

H319 Causes serious eye irritation
Serious eye damage/eye irritation

H335 May cause respiratory irritation
Specific target organ toxicity, single exposure; Respiratory tract irritation

Synonyms & References

English

Eritromicina A carbonato
Erythromycin cyclocarbonate
CHEMBL4788726
Eritromicina A carbonato [Spanish]
HY-100584
CHEBI:135881
UNII-4H3125L82R
(3aR,4R,7R,8S,9S,10R,11R,13R,15R,15aR)-10-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-ethyl-11-hydroxy-8-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3a,7,9,11,13,15-hexamethyldecahydro-6H-[1,3]dioxolo[4,5-c][1]oxacyclotetradecine-2,6,14(7H)-trione
(3aR,4R,7R,8S,9S,10R,11R,13R,15R,15aR)-10-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-4-ethyl-11-hydroxy-8-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3a,7,9,11,13,15-hexamethyl-tetradecahydro-[1,3]dioxolo[4,5-c]oxacyclotetradecane-2,6,14-trione
CCG-270443
Cykliczny weglan erytromycyny A [Polish]
(1R,2R,5R,6S,7S,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-hydroxy-6-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-1,5,7,9,11,13-hexamethyl-3,15,17-trioxabicyclo[12.3.0]heptadecane-4,12,16-trione
s7550
Q27259580
Erythromycin A cyclic carbonate
Erythromycin, cyclic 11,12-carbonate
Erythromycin A cyclic 11,12-carbonate
DTXSID801031707
4H3125L82R
ERYTHROMYCIN CYCLOCARBONATE [WHO-DD]
NCGC00386404-01
Dravercin
55224-05-0
11054-95-8
Carbonato ciclico de eritromicina A
Erythromycin A 11,12-carbonate
Carbonato ciclico de eritromicina A [Spanish]
Davercin
(3aR,4R,7R,8S,9S,10R,11R,13R,15R,15aR)-10-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-ethyl-11-hydroxy-8-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3a,7,9,11,13,15-hexamethyloctahy
CS-6076
AKOS037515854

MDL Number

MFCD01729176

FAQ

What regulatory guidelines apply to Erythromycin Cyclocarbonate (CAS: 55224-05-0)?

Erythromycin Cyclocarbonate (CAS: 55224-05-0) falls under the范畴 of GHS (Global Harmonized System of Classification and Labeling of Chemicals) for health hazards. In the EU, it is regulated under REACH, and in the US, it is subject to FDA and EPA guidelines for pharmaceutical and environmental safety. Specific handling and disposal instructions must be followed to ensure compliance with local and international regulations.

Are there alternatives to Erythromycin Cyclocarbonate in synthesis (CAS: 55224-05-0)?

Several alternatives to Erythromycin Cyclocarbonate exist, including erythromycin estolate and erythromycin stearate. These compounds may offer similar antimicrobial properties but with different stability and solubility profiles. In synthesis, researchers often explore these alternatives to achieve better yields and product quality.

What is the market or research trend for Erythromycin Cyclocarbonate (CAS: 55224-05-0)?

The market for Erythromycin Cyclocarbonate (CAS: 55224-05-0) is driven by its antimicrobial properties, particularly against Gram-positive bacteria. Research trends focus on developing more stable and effective formulations. Price trends indicate ongoing stability, but there is increasing interest in exploring new derivatives and analogs for enhanced therapeutic efficacy and reduced side effects.

How should waste containing Erythromycin Cyclocarbonate (CAS: 55224-05-0) be handled?

Waste containing Erythromycin Cyclocarbonate (CAS: 55224-05-0) should be collected in appropriate containers and stored separately to prevent environmental contamination. For disposal, professional waste management services should be utilized. Incineration is recommended for efficient and safe destruction, ensuring that all compounds are properly treated to meet regulatory standards for environmental protection.